Edition:
United Kingdom

argenx SE (ARGX.OQ)

ARGX.OQ on NASDAQ Stock Exchange Global Select Market

100.00USD
8:59pm GMT
Change (% chg)

$-0.04 (-0.04%)
Prev Close
$100.04
Open
$101.28
Day's High
$101.46
Day's Low
$98.75
Volume
28,045
Avg. Vol
70,082
52-wk High
$111.34
52-wk Low
$41.50

Summary

Name Age Since Current Position

Peter Verhaeghe

59 2014 Non-Executive Chairman of the Board

Tim Van Hauwermeiren

46 2014 Chief Executive Officer, Member of the Board

Werner Lanthaler

50 2014 Non-Executive Vice Chairman of the Board

Eric Castaldi

53 2014 Chief Financial Officer

Hans de Haard

58 Chief Scientific Officer

Rebecca McLeod

Vice President Marketing

Trevor Leighton

Vice President Market Access

Michael Saunders

VP External Research

Luc Van Rompaey

VP Translational Medicine

Debbie Allen

58 Senior Director, Business Development

Dirk Beeusaert

53 2017 General Counsel

Torsten Dreier

53 2008 Chief Development Officer

Nicolas Leupin

44 2016 MD, MBA, Chief Medical Officer

Joseph De Bethizy

67 2015 Non-Executive Member of the Board

Pamela Klein

56 2016 Non-Executive Member of the Board

David Lacey

66 2014 Non-Executive Member of the Board

A.A. Rosenberg

65 2017 Non-Executive Director

Biographies

Name Description

Peter Verhaeghe

Mr. Peter Verhaeghe serves as Non-Executive Chairman of the Board at argenx SE since July 2014. Mr. Verhaeghe is the managing partner of VVGB Advocaten—Avocats, a corporate finance law and tax law firm, a position he has held since July 1999. He is currently lead counsel to a number of Belgian, Dutch and Swiss biotechnology and diagnostics companies. Mr. Verhaeghe currently serves as the president of the board of directors of Merisant France SAS, as a member of the management board of Merisant Company 2 s ` arl and as a member of the board of directors of CzechPak Manufacturing s.r.o. He previously served as the chairman of the board of directors of PharmaNeuroBoost NV from December 2006 to January 2013 and as liquidator in charge of KBC Private Equity Fund Biotech NV from April 2009 to December 2012. Mr. Verhaeghe holds a degree in law from the University of Leuven 1981, and an LLM degree from Harvard Law School 1984. He is member of Audit committee, Remuneration and Nomination committee

Tim Van Hauwermeiren

Mr. Tim Van Hauwermeiren serves as Chief Executive Officer, Member of the Board at argenx SE. Mr Tim Van Hauwermeiren co-founded of the company in July 15, 2008 and has served as Chief Executive Officer since July 2008. Mr. Tim has 20 years of business development and operational management experience within the biotech and consumer goods sectors. During which time he has played a key role in a number of fund raisings, IPO and the negotiation of a number of major licensing deals. Prior to becoming CEO of arGEN-X, he was senior Business Development Manager at Ablynx NV where we was part of the team that negotiated a $265 million research & development deal with Boehringer Ingelheim in 2007. Prior to joining Ablynx, Tim held various management positions with the Procter & Gamble Company in R&D and Business Development, where he conceived and developed several new products. Among those was a healthcare innovation which won the United Nations ICC World Business Award in 2004. Tim holds a Master of Science degree in Bio-engineering from the University of Gent (Belgium) and received general management training at INSEAD and The Vlerick School of Management (Executive MBA).

Werner Lanthaler

Dr. Werner Lanthaler serves as Non-Executive Vice Chairman of the Board at argenx SE since July 2014. Dr. Lanthaler is the chief executive officer of Evotec AG, a global drug discovery research organization, a position he has held since March 2009. Dr. Lanthaler previously served on the supervisory boards of Bioxell SpA and Pantec Biosolutions AG. Dr. Lanthaler holds a degree in psychology, a Ph. D. in business administration from Vienna University of Economics and Business and a Master’s degree in public administration from Harvard University. He is the chairman of Audit committee, and member of Remuneration and Nomination committee.

Eric Castaldi

Mr. Eric Castaldi serves as Chief Financial Officer at argenx SE. He was Chief Financial Officer, Member of the Board from July 2014 until April 26, 2017. Mr. Castaldi has 28 years of international financial executive management experience, including 19 years in the biopharmaceutical industry. Before joining arGEN-X, Mr. Castaldi was CFO from 1998 to 2013 at Nicox, a Euronext-listed biotech company. At Nicox, he was a member of the Executive committee and participated in all the financings of the company since its IPO in November 1999. From 2008 to 2012 he also served as board member and chairman of the audit committee of Hybrigenics, a French biopharmaceutical company specialized in oncology and listed on Euronext. Prior to this he was CFO at Safety Kleen Corporation, a US-based environmental waste company, where he was responsible for operations in France and Belgium. From 1989 through 1997, he was CFO in charge of French and German operations, at My Kinda Town plc, a European leisure company. During that period, he was involved in the 1994 flotation of that company on the London Stock Exchange. From 1986 through 1989, he was employed as Financial Analyst at the Research and Development Centre, located in Sophia Antipolis, of Cordis Corporation, a US-based company specialized in bio-surgical instrumentation. He graduated in Finance, Accountancy and Administration from the University of Nice in 1986.

Hans de Haard

Prof. Hans de Haard is the Chief Scientific Officer of argenx SE. He is a serial pioneer of antibody platforms and has been active in the antibody engineering field since 1989, initially at AKZO Nobel. Subsequently, at the University of Maastricht, he created a large non-immune human Fab library that subsequently became a core asset of Dyax, yielding multiple therapeutic antibodies including ImClone products IMC-A12, IMC-1F8 and the recently approved anti-VEGFR2 antibody ramucirumab (formerly called IMC-1121B). From 1998 to 2002 he was responsible for the discovery of llama VHH-based products at Unilever. From 2002 until he joined argenx, Prof. de Haard worked at Ablynx NV as Director Technology Development, and latterly as Senior Director Discovery Research. He was responsible for setting up the Nanobody® discovery engine and introduced VHH formatting, which turned out to be a major advantage of this platform. He was centrally involved in the development of the Nanoclone® methodology based on B cell selection. During his career, Prof. de Haard has discovered numerous therapeutic antibody leads, seven of which are now progressing in the clinic. He holds a Master of Science in Biochemistry and a PhD in Molecular Immunology from the University of Maastricht. He is a Professor of Immunology at University of Franche Comté (Besançon, France).

Rebecca McLeod

Ms. Rebecca McLeod serves as Vice President Marketing at argenx SE. She has almost 20 years as a proven biopharmaceutical leader. Prior to joining argenx, she was most recently Executive Director, Sales at Alexion Pharmaceuticals. Prior to this she was the Head of Alexion US Marketing for atypical hemolytic uremic syndrome (aHUS), leading strategic vision and tactical implementation for the company’s largest revenue generating market. Earlier in her career, she held positions of increasing responsibility in sales and marketing roles with Takeda Pharmaceuticals North America. Ms. Rebecca Rupert has a Master’s of Business Administration, Marketing from The University of Arkansas, Little Rock and a Bachelor of Business Administration with a focus on marketing from the University of Mississippi.

Trevor Leighton

Mr. Trevor Leighton serves as Vice President Market Access at argenx SE. He has over 20 years proven experience in market access and strategic planning Trevor joined argenx after completing a short period consulting. Prior to this Mr. Trevor worked for Shire, which he joined in 2007 to establish an International Speciality Market Access capability, where none existed previously, going on to become Head of International Market Access and then Head of Global Value Strategy & Access for Shire specialty and rare disease portfolios. With Shire, Trevor and the team he built supported multiple successful launches of new therapies across six continents. Trevor joined Shire after 17 years with Novartis first in the UK and then in Basel, Switzerland where he became Head of Market Access & Health Economics for the Respiratory & Dermatology Business Franchises including the launch of omalizumab for severe allergic asthma outside of the USA. Trevor has a Master’s in Business Administration from the University of Brunel / Henley Management College, a Diploma in Marketing from the UK Chartered Institute of Marketing and a Bachelors degree in Zoology with Botany from the University of London.

Michael Saunders

Dr. Michael Saunders serves as VP External Research at argenx SE. He was Senior Director, Targets & Programs of argenx SE. He has been discovering novel drugs and selecting therapeutic targets for 25 years. At argenx for more than 6 years. He has contributed to the discovery of four antibodies in clinical and preclinical development, for establishment and maintenance of academic collaborations and Alliance Management with Pharma partners (Shire, Bayer, Eli Lilly) and obtaining 4 Research Grants (>9M€). Prior to joining argenx, Michael Saunders working for Ablynx NV as an independent senior interim project director leading the successful Nanobody Landgrab program selecting 100 therapeutic targets, and resulting in the identification of Nanobodies of therapeutic relevance against these targets, 20 patent applications, 4 internal drug development programs and 5 scientific publications. Within Ablynx Michael also led an internal drug discovery program and an external program as Alliance Manager with Boehringer Ingelheim. Previously he was Director Pharma Discovery at Devgen and between 1992 and 2001 Senior Scientist and Project Leader at GSK at the French Drug Discovery Unit. Michael Saunders holds at M.A. from Cambridge University (UK), a PhD in Biology from the University North Carolina (USA) and undertook postdoctoral training in the laboratory of Professor Pierre Chambon in Strasbourg (France). He also received general management training (EMBA) at ESSEC (France) and Mannheim Business School (Germany).

Luc Van Rompaey

Dr. Luc Van Rompaey serves as VP Translational Medicine at argenx SE. He is a senior R&D professional with over 18 years Life Sciences experience. Before joining argenx, Luc played a pivotal role in the development of Galapagos NV which he joined soon after its inception. He made important contributions to the successful implementation of the functional genomics platform, discovering novel osteoporosis targets that were outlicensed to Procter&Gamble, Wyeth and Eli Lilly. He was instrumental in transitioning Galapagos’ operations from target to drug discovery research. He started the JAK inhibitor research program, led the discovery and contributed to the Development of the JAK1 inhibitor GLPG0634, currently undergoing Phase II trials in rheumatoid arthritis and Crohn’s disease. He served on alliance management teams for drug discovery collaborations with GSK, Eli Lilly and Servier in the fields of osteoarthritis, immunity & inflammation, osteoporosis and oncology. Prior to joining Galapagos he performed postdoctoral research in tumor biology in St. Jude Children’s Research Hospital (US) and Leuven University (Belgium).

Debbie Allen

Dr. Debbie Allen serves as Senior Director, Business Development at argenx SE. Debbie has been active in the antibody engineering field since the 1980s. She brings to arGEN-X more than 30 years of corporate and business development experience with small and large biotech companies focused on biopharmaceuticals. She established her Business Development career at Cambridge Antibody Technology (now MedImmune), where she had management responsibility for technology, intellectual property and product out-licensing, corporate equity, co-development and cross-license agreements. She was responsible for the 1999 license agreement with Human Genome Sciences that led to the discovery of the monoclonal antibody drug BENLYSTA (belimumab), now approved for the treatment of systemic lupus erythematosus. Prior to joining arGEN-X, Debbie acted for eight years as an independent consultant to around 25 emerging biotech companies, providing strategic management and business development support. Dr. Allen holds an B. Sc. in cellular pathology from the University of Bristol and a Ph. D. in viral oncology from the University of London.

Dirk Beeusaert

Mr. Dirk Beeusaert serves as General Counsel at argenx SE since April 1, 2017. Mr. Beeusaert has extensive general experience in corporate governance and as general counsel of a listed company. Mr. Beeusaert worked in various roles from February 1996 to July 2016 for Gimv NV, a European private equity company listed on Euronext Brussels, including chief legal officer from January 2001 to 2006, and general counsel from 2006 to July 2016, where he was co-responsible for operations and corporate governance. Mr. Beeusaert currently serves as a member of the boards of directors of Pragma Capital SAS and Cubigo NV. Mr. Beeusaert holds a Bachelor in Law and a Master Law degree from Ghent University and an MBA in Fiscal Studies and Accounting Research, Tax and Accounting from Vlerick School of Management.

Torsten Dreier

Dr. Torsten Dreier is the Chief Development Officer of argenx SE since May 2008. He has been developing antibodies for more than 20 years and progressed six antibody products from preclinical research into clinical trials. Prior to joining argenx, he was Director of Therapeutic Drug Development and Senior Director Preclinical Development at Ablynx NV, with overall responsibility for pharmacology, toxicology, bioanalytics and CMC as well as early clinical development. Between 1997-2003, Dr. Dreier worked as Director Preclinical Development at Micromet AG in Munich, Germany, on the preclinical characterization of recombinant antibodies and BiTEs. He holds a PhD in Biochemistry from the University of Tübingen, Germany. In 1995, he joined the group of Prof. Ralf A. Reisfeld at the Scripps Research Institute in La Jolla, CA as a postdoctoral researcher and extended his know-how in immunology with his work on immunocytokines (recombinant antibody cytokine fusion proteins), recombinant antibodies and cytokines.

Nicolas Leupin

Dr. Nicolas Leupin serves as MD, MBA, Chief Medical Officer at argenx SE since February 2016. Dr. Leupin has clinical and industry expertise in medical oncology as well as experience in drug development. He currently lectures at the University of Bern. From 2008 to 2015, Dr. Leupin served in different positions in clinical development at Celgene, including Director of Clinical Development of EMEA Celgene, where he contributed to building the clinical development department in Europe and then led the European lymphoma and myeloma teams, served as clinical lead for several compounds up to phase III clinical trials, and was responsible for running and managing hematology and oncology clinical trials, including both industry-sponsored trials and academic cooperative groups, several of them through to registration. Among other activities, he was responsible for specific clinical documents of registration dossiers that lead to European and American registrations. Dr. Leupin holds an MBA from Jones International University and an M. D. from the University of Bern and was board certified in medical oncology (Switzerland).

Joseph De Bethizy

Dr. Joseph Donald De Bethizy has served as a Non-Executive Member of the Board at argenx SE since May 2015. He has 30 years of experience in research and development and financial, business and operating management in the biotechnology and consumer products industry. He is the president of White City Consulting ApS. Previously, Dr. De Bethizy served as president and chief executive officer of Santaris Pharma A/S until October 2014, when the company was sold to Roche. From August 2000 to June 2012, Dr. De Bethizy was co-founder and chief executive officer of Targacept, Inc., a U.S. biotechnology company listed on Nasdaq. He currently serves on the supervisory boards of Albumedix A/S, Newron Pharmaceuticals SpA, Noxxon Pharma NV and AG, Rigontec GmbH and Proterris, Inc. From May 2013 to November 2014, he served as executive chairman of Contera Pharma ApS. He previously served on the boards of Asceneuron SA, Serendex Pharmaceuticals A/S, Enbiotix Inc., Targacept Inc. and Biosource Inc. Dr. De Bethizy has held adjunct appointments at Wake Forest University Babcock School of Management, Wake Forest University School of Medicine and Duke University. Mr. deBethizy holds a B. Sc. in biology from the University of Maryland, and an M. Sc. and a Ph. D. in toxicology from Utah State University. He is member of Research and Development committee, and the chairman of Remuneration and Nomination committee.

Pamela Klein

Dr. Pamela Klein serves as Non-Executive Member of the Board at argenx SE since April 2016. Dr. Klein is a principal and founder of PMK BioResearch, which offers strategic consulting in oncology drug development to corporate boards, management teams and the investment community, a position she has held since 2008. She currently serves as a member of various scientific advisor boards. Previously, Dr. Klein spent seven years at the National Cancer Institute as Research Director of the NCI-Navy Breast Center, after which she joined Genentech and was VP, Development until 2001. She served as Chief Medical Officer for Intellikine which was acquired by Takeda. She was previously Vice President, Development for Genentech. Dr. Klein holds a Bachelor’s degree in biology from California State University and an M. D. from Stritch School of Medicine, Loyola University Chicago and is trained in internal medicine and medical oncology. She is member of Research and Development committee

David Lacey

Dr. David L. Lacey serves as Non-Executive Member of the Board at argenx SE. He was Member of the Supervisory Board of arGEN-X BV since July 2014. Dr. Lacey is a biopharmaceutical consultant at David L. Lacey LLC, where he advises academic institutions, biotechnology companies and venture capital firms, a position he has held since July 2011. He currently serves as a director of Inbiomotion SL, Atreca, Inc. and Nurix, Inc. From 1994 until his retirement in 2011, he held various positions, including head of discovery research, at Amgen Inc., where he played a fundamental scientific role in the discovery of the OPG/ RANKL/RANK pathway, which led to the development of the anti- RANKL human mAb denosumab, for both osteoporosis (Prolia) and cancer-related bone diseases (XGEVA). He holds a Bachelor’s degree in biology and an M. D. from the University of Colorado, and has his board certification in anatomic pathology. He is the chairman of Research and Development committee.

A.A. Rosenberg

Mr. A.A. Rosenberg has served as Non-Executive Member of the Board at argenx SE since April 2017. He currently serves as CEO of TR Advisory Services GmbH, a consultancy firm advising on business development, licensing and mergers and acquisitions. Mr. Rosenberg has also been a Managing Director of MPM Capital, a venture capital firm, since April 2015. From January 2013 until February 2015, he served as Corporate Head of M&A and Licensing at Novartis Pharma. He served as Global Head of Business Development and Licensing at Novartis Pharma from March 2005 to December 2012. Msc. A. A. Rosenberg holds non-executive board memberships in Idenix Pharmaceuticals, Radius Health Inc., TriNetX, Inc., Clinical Ink, Inc., iOmx Therapeutics AG and Cullinan Oncology Inc. Msc. A. A. Rosenberg has a B. Sc. (Hons) from the University of Leicester and a M. Sc. Physiology from the University of London. He is member of Audit committee.